메뉴 건너뛰기
Blood
Volumn 107, Issue 9, 2006, Pages 3420-3421
No RIC in high-risk myeloma?
Author keywords

[No Author keywords available]
Indexed keywords

BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE;
EID: 33646404607     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-02-001768     Document Type: Note
Times cited : (9)
References (6)
  • 1
    • 33646411095 scopus 로고    scopus 로고
    • Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case matched study from the European Group for Blood and Marrow Transplantation
    • Bjorkstrand B, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;87:1196-1198.
    • (1996) Blood , vol.87 , pp. 1196-1198
    • Bjorkstrand, B.1    Ljungman, P.2    Svensson, H.3
  • 2
    • 0041438792 scopus 로고    scopus 로고
    • Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma
    • Corradini P, Cavo M, Lokhorst H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003;102:1927-1929.
    • (2003) Blood , vol.102 , pp. 1927-1929
    • Corradini, P.1    Cavo, M.2    Lokhorst, H.3
  • 3
    • 2542448169 scopus 로고    scopus 로고
    • The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
    • Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood. 2004;103:4362-4364.
    • (2004) Blood , vol.103 , pp. 4362-4364
    • Lokhorst, H.M.1    Wu, K.2    Verdonck, L.F.3
  • 4
    • 0142152420 scopus 로고    scopus 로고
    • Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
    • Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102:3447-3454.
    • (2003) Blood , vol.102 , pp. 3447-3454
    • Maloney, D.G.1    Molina, A.J.2    Sahebi, F.3
  • 5
    • 8644231815 scopus 로고    scopus 로고
    • Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma
    • Kröger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood. 2004;104:3361-3363.
    • (2004) Blood , vol.104 , pp. 3361-3363
    • Kröger, N.1    Shimoni, A.2    Zagrivnaja, M.3
  • 6
    • 84858872031 scopus 로고    scopus 로고
    • Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma
    • In press
    • van de Donk NWCJ, Kröger N, Hegenbart U, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma [letter]. Blood. In press.
    • Blood
    • Van De Donk, N.W.C.J.1    Kröger, N.2    Hegenbart, U.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.